Study To Evaluate The Immunogenicity And Safety Of r-hIFN Beta-1a (Rebif®) Using Clone 484-39 In Multiple Sclerosis
Clinical trial NCT00367484 · COMPLETED
Trial details
- NCT number
- NCT00367484
- Sponsor
- Merck KGaA, Darmstadt, Germany
- Status
- COMPLETED
- Phase
- Phase 4
- Study type
- INTERVENTIONAL
- Start date
- 2004-05-01
- Primary completion
- 2006-01-01
- Enrollment
- 460
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.